Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP
8 other identifiers
interventional
20,000
28 countries
407
Brief Summary
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2016
Longer than P75 for phase_3
407 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 11, 2015
CompletedStudy Start
First participant enrolled
April 11, 2016
CompletedFirst Posted
Study publicly available on registry
April 13, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2028
ExpectedJuly 12, 2024
July 1, 2024
9.8 years
December 11, 2015
July 10, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
All-cause mortality
Day 90
Days alive and not receiving organ support in ICU
Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Day 21
Secondary Outcomes (11)
ICU Mortality
Day 90
ICU length of stay
Day 90
Hospital length of stay
Day 90
Ventilator free days
Day 28
Organ failure free days
Day 28
- +6 more secondary outcomes
Other Outcomes (16)
Occurrence of multi-resistant organism colonisation/infection
Day 90, censored at hospital discharge
Occurrence clostridium difficile
Day 90, censored at hospital discharge
Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death
Day 90, censored at hospital discharge
- +13 more other outcomes
Study Arms (18)
Antibiotic Domain
OTHERPatients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions. Note: the ceftaroline + macrolide intervention has been closed to recruitment.
Macrolide Duration Domain
OTHERPatients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
Corticosteroid Domain
OTHERPatients with community acquired pneumonia (CAP) admitted to participating hospitals will be randomised to a steroid use strategy. Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19. Note: the fixed-course hydrocortisone has been closed to recruitment
Influenza Antiviral Domain
OTHERPatients with community-acquired pneumonia admitted to participating hospitals with microbiological testing confirmed influenza infection will be randomised to one of six interventions.
COVID-19 Antiviral Domain
OTHERPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin. Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control. This domain is now closed.
COVID-19 Immune Modulation Domain
OTHERPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions. Note: this domain is now closed.
Anticoagulation Domain
OTHERPatients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy. Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed.
Immunoglobulin Domain
OTHERImmunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma. Note: an earlier version of this domain was not restricted to immunosuppressed patients.
Vitamin C Domain
OTHERPatients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C. Note: this domain is now closed.
Simvastatin Domain
OTHERPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin. Note: this domain is now closed.
Antiplatelet Domain
OTHERPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor. Note: this domain is now closed.
Mechanical Ventilation Domain
OTHERPatients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
COVID-19 Immune Modulation (2) Domain
OTHERPatients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions. Note: this domain is now closed.
ACE2 RAS Domain
OTHERPatients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies. Note: this domain is now closed.
Cysteamine Domain
OTHERPatients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine. Note: this domain is now closed.
Endothelial Domain
OTHERPatients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.
Influenza Immune Modulation
OTHERPatients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.
COVID-19 Antiviral (II) Domain
OTHERPatients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.
Interventions
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice. Note: this intervention is now closed.
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5. The dosing of and route of administration is not protocolised, the following guidance is provided: * Initial IV administration of a macrolide is strongly preferred * The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. * The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first). The dosing of and route of administration is not protocolised, the following guidance is provided: * Initial IV administration of a macrolide is strongly preferred * The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. * The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention is now closed.
50mg IV hydrocortisone every 6 hours while the patient is in septic shock
100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.
No antiviral agent intended to be active against influenza infection is to be administered
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Note: this intervention is now closed.
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed.
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed.
Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day. Note: this intervention is now closed.
No immune modulating agent intended to be active against COVID-19 is to be administered. Note: this intervention is now closed.
IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first. Note: this intervention is now closed.
A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours. In patients with renal impairment, anakinra will be administered on alternate days. Note: this intervention is now closed.
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period. Note: this intervention is now closed.
Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period. Note: this intervention is now closed.
Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician. Note: this intervention is now closed.
Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
Note: this intervention is now closed.
No high dose intravenous vitamin C is to be administered Note: this intervention is now closed.
Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses Note: this intervention is now closed.
No antiplatelet agent or NSAID to be administered. Note: this intervention is now closed.
Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
Site-selected P2Y12 inhibitor: * Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first. * Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day. * Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
No simvastatin intended to be active against COVID-19 is to be administered Note: this intervention is now closed.
Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation Note: this intervention is now closed.
Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital Note: this intervention is now closed.
Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10. Note: this intervention is now closed.
Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.
Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first. ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily. Note: this intervention is now closed.
No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first. Note: this intervention is now closed.
Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first. Note: this intervention is now closed.
6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
Baloxavir marboxil administered on days 1 and 4 post-randomisation.
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
No immune modulating agent intended to be active against influenza is to be administered.
Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Eligibility Criteria
You may qualify if:
- Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
- symptoms or signs or both that are consistent with lower respiratory tract infection AND
- Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
- Up to 48 hours after ICU admission, receiving organ support with one or more of:
- Non-invasive or Invasive ventilatory support;
- Receiving infusion of vasopressor or inotropes or both
You may not qualify if:
- Healthcare-associated pneumonia:
- Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
- Resident of a nursing home or long term care facility
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Previous participation in this REMAP within the last 90 days
- \. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.
- Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
- Patient is expected to be discharged from hospital today or tomorrow
- More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
- Previous participation in this REMAP within the last 90 days
- DOMAIN-SPECIFIC ELIGIBLE CRITERIA:
- Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UMC Utrechtlead
- Australian and New Zealand Intensive Care Research Centrecollaborator
- Medical Research Institute of New Zealandcollaborator
- Unity Healthcollaborator
- Berry Consultantscollaborator
- Global Coalition for Adaptive Researchcollaborator
- University of Pittsburgh Medical Centercollaborator
- Intensive Care National Audit & Research Centrecollaborator
- St. Marianna University School of Medicinecollaborator
- Nat Intensive Care Surveillance - MORUcollaborator
- National University Hospital, Singaporecollaborator
Study Sites (408)
University of Florida
Jacksonville, Florida, 32209, United States
Augusta University
Augusta, Georgia, 30912, United States
University of Illinois Health
Chicago, Illinois, 60612, United States
Tulane Medical Center
New Orleans, Louisiana, 70112, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27157-1009, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
Oregon Health and Science University
Portland, Oregon, 97239-3098, United States
University of Pittsburgh Medical Centre
Pittsburgh, Pennsylvania, United States
Brown University - Rhode Island Hospital
Providence, Rhode Island, 02903, United States
Canberra Hospital
Canberra, Australian Capital Territory, 2605, Australia
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, 2200, Australia
Blacktown Hospital
Blacktown, New South Wales, 2148, Australia
Campbelltown Hospital
Campbelltown, New South Wales, 2560, Australia
Sutherland Hospital
Caringbah, New South Wales, 2229, Australia
Concord Hospital
Concord, New South Wales, 2139, Australia
Dubbo Base Hospital
Dubbo, New South Wales, 2830, Australia
Northern Beaches Hospital
Frenchs Forest, New South Wales, 2086, Australia
Nepean Hospital
Kingswood, New South Wales, 2750, Australia
St. George Hospital
Kogarah, New South Wales, 2217, Australia
Liverpool Hospital
Liverpool, New South Wales, 2170, Australia
John Hunter Hospital
Newcastle, New South Wales, 2305, Australia
Orange Health Service
Orange, New South Wales, 2800, Australia
St Vincent's Hospital Sydney
Sydney, New South Wales, 2010, Australia
Prince of Wales Hospital
Sydney, New South Wales, 2031, Australia
Royal Prince Alfred Hospital
Sydney, New South Wales, 2050, Australia
Royal North Shore Hospital
Sydney, New South Wales, 2065, Australia
Wollongong Hospital
Sydney, New South Wales, 2500, Australia
Wagga Wagga Base Hospital
Wagga Wagga, New South Wales, 2650, Australia
Westmead Hospital
Westmead, New South Wales, 2145, Australia
Royal Darwin Hospital,
Darwin, Northern Territory, 0810, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, 4575, Australia
The Prince Charles Hospital
Brisbane, Queensland, 4032, Australia
Mater Hospital Brisbane
Brisbane, Queensland, 4101, Australia
Princess Alexandra Hospital
Brisbane, Queensland, 4102, Australia
Caboolture Hospital
Caboolture, Queensland, 4510, Australia
Queen Elizabeth II Jubilee Hospital
Coopers Plains, Queensland, 4110, Australia
Logan Hospital
Logan City, Queensland, 4129, Australia
Redcliffe Hospital
Redcliffe, Queensland, 4020, Australia
Rockhampton Hospital
Rockhampton, Queensland, 4700, Australia
Gold Coast University Hospital
Southport, Queensland, 4215, Australia
Toowoomba Hospital
Toowoomba, Queensland, 4350, Australia
Townsville Hospital
Townsville, Queensland, 4814, Australia
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
The Queen Elizabeth Hospital
Adelaide, South Australia, 5011, Australia
Lyell McEwin Hospital
Adelaide, South Australia, 5112, Australia
Flinders Medical Centre
Bedford Park, South Australia, 5042, Australia
Launceston Hospital
Launceston, Tasmania, 7250, Australia
Ballarat Base Hospital
Ballarat, Victoria, 3350, Australia
Bendigo Hospital
Bendigo, Victoria, 3550, Australia
Casey Hospital
Berwick, Victoria, 3806, Australia
Box Hill Hospital
Box Hill, Victoria, 3128, Australia
Monash Medical Centre
Clayton, Victoria, 3168, Australia
Dandenong Hospital
Dandenong, Victoria, 3175, Australia
Angliss Hospital
Ferntree Gully, Victoria, 3156, Australia
Footscray Hospital
Footscray, Victoria, 3011, Australia
University Hosptial Geelong
Geelong, Victoria, 3220, Australia
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
Royal Melbourne Hospital
Melbourne, Victoria, 3050, Australia
St Vincent's Hospital Melbourne
Melbourne, Victoria, 3065, Australia
Maroondah Hospital
Ringwood East, Victoria, 3135, Australia
Sunshine Hospital
Sunshine, Victoria, 3021, Australia
Werribee Mercy Hospital
Werribee, Victoria, 3030, Australia
St John of God Hospital Midland
Midland, Western Australia, 6056, Australia
St John of God Hospital Murdoch
Murdoch, Western Australia, 6150, Australia
Royal Perth Hospital
Perth, Western Australia, 6000, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, 6009, Australia
Fiona Stanley Hospital
Perth, Western Australia, 6150, Australia
St John of God Subiaco
Subiaco, Western Australia, 6008, Australia
CHU de Charleroi - HĂ´pital Civil Marie Curie
Charleroi, 6042, Belgium
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
CHU Namur site Godinne
Namur, 5530, Belgium
Foothills Medical Centre
Calgary, Alberta, T2W 1S7, Canada
Peter Lougheed Centre
Calgary, Alberta, T2W 1S7, Canada
Rockyview General Hospital
Calgary, Alberta, T2W 1S7, Canada
South Health Campus
Calgary, Alberta, T2W 1S7, Canada
Royal Alexandra Hospital, Alberta
Edmonton, Alberta, T5H 3V9, Canada
University of Alberta Hospital
Edmonton, Alberta, T6G 2C8, Canada
Surrey Memorial Hospital
Surrey, British Columbia, V3V 1Z2, Canada
St Boniface General Hospital
Winnipeg, Manitoba, R2H 2A6, Canada
Health Sciences Centre Winnipeg
Winnipeg, Manitoba, R3A 1R9, Canada
Grace Hospital
Winnipeg, Manitoba, R3J 3M7, Canada
Dr. Everett Chalmers Regional Hospital
Fredericton, New Brunswick, E3B 4R3, Canada
The Moncton Hospital
Fredericton, New Brunswick, E3B 4R3, Canada
The Saint John General Hospital
Fredericton, New Brunswick, E3B 4R3, Canada
William Osler Health System
Brampton, Ontario, L6R 3J7, Canada
Brantford General Hospital
Brantford, Ontario, N3R 1G9, Canada
Hamilton general Hospital
Hamilton, Ontario, L8L 8E7, Canada
Juravinski Hospital
Hamilton, Ontario, L8L 8E7, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6, Canada
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
Grand River Hospital
Kitchener, Ontario, N2G 4K9, Canada
St Mary's General Hospital
Kitchener, Ontario, N2M 1B2, Canada
The Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
Niagara Health
Saint Catharines, Ontario, L2S 0A9, Canada
Thunder Bay General Hospital
Thunder Bay, Ontario, P7B 6V4, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
St. Michael's Hospital Unity Health Toronto
Toronto, Ontario, M5B 1W8, Canada
Mount Sinai Hospital
Toronto, Ontario, M5G 1X5, Canada
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
St Joseph's Health Centre
Toronto, Ontario, M6R 1B5, Canada
CIUSS Chaudieres-Appalaches (Levis)
LĂ©vis, Quebec, G6V 3Z1, Canada
Hospital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4, Canada
HĂ´pital Fleury
Montreal, Quebec, H2B 1K3, Canada
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 0A9, Canada
McGill University Health Centre
Montreal, Quebec, H3H 2R9, Canada
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, H4J 1C5, Canada
CHU de Québec - Université Laval
Québec, Quebec, G1R 2J6, Canada
IUCPQ-UL
Québec, Quebec, G1V 4G5, Canada
Centre Hospitalier de l'Université de Sherbrooke
Sherbrooke, Quebec, J1J 3H5, Canada
Regina General Hospital
Saskatoon, Saskatchewan, S7K 0M7, Canada
Universidad de La Sabana
ChĂa, Cundinamarca, Colombia
General County Hospital Požega
Požega, 34000, Croatia
University Hospital Centre Zagreb
Zagreb, 10000, Croatia
University Hospital for Infectious Diseases
Zagreb, 10000, Croatia
FakultnĂ nemocnice KrĂ¡lovskĂ© Vinohrady
Prague, 10000, Czechia
Teplice Hospital
Teplice, 41501, Czechia
Tartu University Hospital
Tartu, 50406, Estonia
Helsinki University Hospital
Helsinki, 00290, Finland
Tampere University Hospital
Tampere, 33520, Finland
CH Argenteuil
Argenteuil, 95107, France
Centre Hospitalier Henri Mondor d'Aurillac
Aurillac, 15000, France
Beauvais General Hospital
Beauvais, 60000, France
Hopital Nord Franche-Comte
Belfort, 90400, France
Centre hospitalier Bethune Beuvry
BĂ©thune, 62660, France
Ambroise Pare Hospital
Boulogne-Billancourt, 92100, France
CH de Dax
Dax, 40100, France
Centre Hospitalier de Dieppe
Dieppe, 76202, France
CHU Dijon Bourgogne
Dijon, 21000, France
Hopital Simone Veil Eaubonne
Eaubonne, 95600, France
Sud Essonne Hospital Etampes
Étampes, 91150, France
Hospital Raymond Poincare
Garches, 92380, France
CHD Vendee
La Roche-sur-Yon, 85000, France
Centre Hospitalier Le Mans
Le Mans, 72027, France
CHU Dupuytren
Limoges, 87000, France
Centre Hospitalier de Melun
Melun, 77000, France
Centre Hospitalier Layne - Mont-de-Marsan
Mont-de-Marsan, 40024, France
Centre Hospitalier des Pays de Morlaix
Morlaix, 29600, France
CHR d'Orleans
Orléans, 45100, France
Lariboisiere Hospital
Paris, 75010, France
Hopital Tenon
Paris, 75020, France
Nouvel Hopital Civil Strasbourg
Strasbourg, 67000, France
Hopital de Hautepierre Strasbourg
Strasbourg, 67200, France
CHRU Tours Hopital Bretonneau
Tours, 37000, France
Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie
Berlin, 10117, Germany
Vivantes Klinikum Neukölln
Berlin, 12351, Germany
Charite Universitätsmedizin Berlin
Berlin, 13353, Germany
Vivantes Humboldt-Klinikum
Berlin, 13509, Germany
University Hospital of Cologne
Cologne, 50937, Germany
Carl-Thiem-Klinikum Cottbus
Cottbus, 03058, Germany
Klinikum Dortmund
Dortmund, 44137, Germany
Elisabeth Hospital Essen
Essen, 45138, Germany
Universitätsklinikum Frankfurt
Frankfurt, 60590, Germany
University Medical Center Hamburg-Eppendorf (UKE)
Hamburg, 20251, Germany
Universitätsklinikum Jena
Jena, 07747, Germany
University Hospital Leipzig
Leipzig, 04103, Germany
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
Klinikum rechts der Isar der TU MĂ¼nchen
MĂ¼nchen, 81675, Germany
Universitätsklinikum MĂ¼nster
MĂ¼nster, 48149, Germany
Universitäts Klinikum TĂ¼bingen
TĂ¼bingen, 72076, Germany
Universitätsklinikum WĂ¼rzburg
WĂ¼rzburg, 97080, Germany
JĂ³sa AndrĂ¡s County Hospital
NyĂregyhĂ¡za, 4400, Hungary
AlmĂ¡si Balogh PĂ¡l KĂ³rhĂ¡z
Ă“zd, 3600, Hungary
Apollo Main Hospital
Chennai, Tamil Nadu, 600006, India
Apollo First Med Hospital
Chennai, Tamil Nadu, 600010, India
Apollo Vanagaram Hospital
Chennai, Tamil Nadu, 600095, India
Apollo Speciality Hospital - OMR
Chennai, Tamil Nadu, 600096, India
Cork University Hospital
Cork, T12 DC4A, Ireland
Beaumont Hospital
Dublin, Ireland
St. Vincent's University Hospital
Dublin, Ireland
University Hospital Galway
Galway, Ireland
University Hospital Waterford
Waterford, X91 ER8E, Ireland
Rambam Medical Center
Haifa, 3109601, Israel
Beilinson Hospital, Rabin Medical Center
Petah Tikva, 4941492, Israel
The Baruch Padeh Medical Center
Poria – Neve Oved, 1528001, Israel
AO Spedali Civili di Brescia
Brescia, 25123, Italy
Humanitas Research Hospital
Milan, 20089, Italy
Ca' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
IRCCS Ospedale San Raffaele
Milan, 20132, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, 90127, Italy
Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione
Palermo, 90127, Italy
Arcispedale S. Maria Nuova
Reggio Emilia, 42123, Italy
Ospedale Infermi di Rimini
Rimini, 47923, Italy
St Marianna University School of Medicine
Kawasaki, Kanagawa, 216-8511, Japan
Yokohama City University Hospital
Yokohama, Kanagawa, 236-0004, Japan
St. Marianna University Yokohama City Seibu Hospital
Yokohama, Kanagawa, 241-0811, Japan
Saiseikai Kumamoto Hospital
Minami, Kumamoto, 861-4193, Japan
Osaka City General Hospital
Osaka, 534-0021, Japan
Nerima Hikarigaoka Hospital
Tokyo, 130-8575, Japan
Tokyo Metropolitan Bokutoh Hospital
Tokyo, 130-8575, Japan
Itabashi Chuo Medical Center
Tokyo, 174-0051, Japan
Tokyo bay Urayasu-Ichikawa Medical Center
Tokyo, 279-0001, Japan
Wakayama Medical University
Wakayama, 641-8509, Japan
Chitwan Medical College
Bharatpur, 44200, Nepal
Grande International Hospital
Kathmandu, 44600, Nepal
Hospital for Advanced Medicine and Surgery (HAMS)
Kathmandu, 44600, Nepal
Nepal Mediciti
Kathmandu, 44600, Nepal
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
ZGT Almelo
Almelo, 7609PP, Netherlands
Meander Medisch Centrum
Amersfoort, Netherlands
OLVG
Amsterdam, 1091AC, Netherlands
Rijnstate Hospital
Arnhem, 6815AD, Netherlands
Deventer Hospital
Deventer, 7416SE, Netherlands
Ziekenhuis Gelderse Vallei
Ede, 6716RP, Netherlands
Maxima Medisch Centrum Eindhoven
Eindhoven, 5631BM, Netherlands
Martini Hospital Groningen
Groningen, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, 8934AD, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Canisius Wilhelmina Ziekenhuis
Nijmegen, Netherlands
Radboud University Medical Center
Nijmegen, Netherlands
Laurentius Hospital
Roermond, 6043CV, Netherlands
Maasstad Ziekenhuis
Rotterdam, 3079DZ, Netherlands
Hagaziekenhuis
The Hague, 2545AA, Netherlands
Bernhoven Hospital
Uden, 5406PT, Netherlands
University Medical Center Utrecht
Utrecht, 3584 CX, Netherlands
North Shore Hospital
Auckland, 0620, New Zealand
CVICU, Auckland City Hospital
Auckland, 1023, New Zealand
DCCM, Auckland City Hospital
Auckland, 1023, New Zealand
Middlemore Hospital
Auckland, 2104, New Zealand
Christchurch Hospital
Christchurch, 8011, New Zealand
Waikato Hospital
Hamilton, 3204, New Zealand
Taranaki Base Hospital
New Plymouth, 4310, New Zealand
Rotorua Hospital
Rotorua, 3010, New Zealand
Tauranga Hospital
Tauranga, 3112, New Zealand
Wellington Regional Hospital
Wellington, 6021, New Zealand
Whangarei Hospital
Whangarei, 0148, New Zealand
Ziauddin University Hospital Clifton Campus
Karachi, Sindh, 75000, Pakistan
Abbasi Shaheed Hospital
Karachi, Sindh, 75300, Pakistan
National Institute of Cardiovascular Diseases, Karachi
Karachi, Sindh, 75510, Pakistan
South City Hospital, Karachi
Karachi, Sindh, 75600, Pakistan
Ziauddin University North Nazimabad Campus
Karachi, Sindh, Pakistan
Centro Hospitalar do Medio Tejo
Abrantes, Portugal
Hospital Ocidental
Lisbon, 1169-050, Portugal
Hospital LusĂadas Lisbon
Lisbon, Portugal
Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes"
Bucharest, 030303, Romania
King Abdulaziz Medical City
Riyadh, 14611, Saudi Arabia
University Clinical Centre of Serbia
Belgrade, 11000, Serbia
University Hospital Center Dr Dragiša Mišović
Belgrade, 11000, Serbia
Clinical Centre of Niš
Niš, 18000, Serbia
University Clinic of Respiratory and Allergic Diseases Golnik
Golnik, 4204, Slovenia
University Medical Centre Maribor
Maribor, 2000, Slovenia
Hospital del Mar
Barcelona, Spain
Hospital Universitario de Jerez
Cadiz, 11407, Spain
Reina Sofia University Hospital
CĂ³rdoba, 14004, Spain
Ramon y Cajal University Hospital
Madrid, 28034, Spain
Hospital Regional de MĂ¡laga
MĂ¡laga, 29010, Spain
Hospital Universitario de Ourense
Ourense, 32005, Spain
Hospital Marqués de Valdecilla
Santander, 39008, Spain
Hospital Verge de la Cinta
Tortosa, 43500, Spain
Doctor Peset University Hospital
Valencia, 46017, Spain
Hospital La Fe
Valencia, 46026, Spain
University Hospital ZĂ¼rich
Zurich, 8091, Switzerland
Basildon Hospital
Basildon, England, SS16 5NL, United Kingdom
Basingstoke and North Hampshire Hospital
Basingstoke, England, RG24 9NA, United Kingdom
Royal United Hospital, Bath
Bath, England, BA1 3NG, United Kingdom
Queen Elizabeth Hospital Birmingham
Birmingham, England, B15 2TH, United Kingdom
Birmingham City Hospital
Birmingham, England, B18 7QH, United Kingdom
Royal Blackburn Teaching Hospital
Blackburn, England, BB2 3HH, United Kingdom
Pilgrim Hospital ULHT
Boston, England, PE21 9QS, United Kingdom
Royal Bournemouth Hospital
Bournemouth, England, BH7 7DW, United Kingdom
Royal Sussex County Hospital
Brighton, England, BN2 5BE, United Kingdom
Southmead Hospital
Bristol, England, BS10 5NB, United Kingdom
Bristol Royal Infirmary
Bristol, England, BS2 8EX, United Kingdom
Queen's Hospital, Burton
Burton-on-Trent, England, DE13 0RB, United Kingdom
Royal Papworth Hospital
Cambridge, England, CB2 0AY, United Kingdom
Addenbrookes Hospital
Cambridge, England, CB2 0QQ, United Kingdom
North Cumberland Infirmary
Carlisle, England, CA2 7HY, United Kingdom
St Peter's Hospital
Chertsey, England, KT16 0P, United Kingdom
Countess of Chester Hospital
Chester, England, CH2 1UL, United Kingdom
Chesterfield Royal Hospital
Chesterfield, England, S44 5BL, United Kingdom
Colchester Hospital
Colchester, England, CO4 5JL, United Kingdom
University Hospital Coventry
Coventry, England, CV2 2DX, United Kingdom
Darlington Memorial Hospital
Darlington, England, DL3 6HX, United Kingdom
Darent Valley Hospital
Dartford, England, DA2 8DA, United Kingdom
Russells Hall Hospital
Dudley, England, DY1 2HQ, United Kingdom
Royal Devon and Exeter Hospital
Exeter, England, Ex2 5DW, United Kingdom
Frimley Park Hospital
Frimley, England, GU16 7 UJ, United Kingdom
Queen Elizabeth Hospital Gateshead
Gateshead, England, NE9 6SX, United Kingdom
Medway Maritime Hospital
Gillingham, England, ME7 5NY, United Kingdom
James Paget University Hospital
Great Yarmouth, England, NR31 6LA, United Kingdom
Royal Surrey County Hospital
Guildford, England, GU2 7XX, United Kingdom
Northwick Park Hospital
Harrow, England, HA1 3UJ, United Kingdom
Hereford County Hospital
Hereford, England, HR1 2ER, United Kingdom
Barnet Hospital
High Barnet, England, EN5 3DJ, United Kingdom
Huddersfield Royal Infirmary
Huddersfield, England, HD3 3EA, United Kingdom
King George Hospital
Ilford, England, IG3 8YB, United Kingdom
Ipswich Hospital
Ipswich, England, IP4 5PD, United Kingdom
Kettering Hospital
Kettering, England, NN16 8UZ, United Kingdom
Leeds General Infirmary
Leeds, England, LS9 7TF, United Kingdom
Leicester Royal Infirmary
Leicester, England, LE1 5WW, United Kingdom
Glenfield Hospital
Leicester, England, LE3 9QP, United Kingdom
Lincoln County Hospital
Lincoln, England, LN2 5QY, United Kingdom
Liverpool Heart and Chest Hospital
Liverpool, England, L14 3PE, United Kingdom
Alder Hey Hospital
Liverpool, England, L14 5AB, United Kingdom
Royal Liverpool University Hospital
Liverpool, England, L7 8XP, United Kingdom
University Hospital Aintree
Liverpool, England, L9 7AL, United Kingdom
Croydon University Hospital
London, England, CR7 7YE, United Kingdom
Royal London Hospital
London, England, E1 1FR, United Kingdom
Whipps Cross Hospital
London, England, E11 1NR, United Kingdom
Newham University Hospital
London, England, E13 8SL, United Kingdom
St Bartholomew's Hospital
London, England, EC1A 7BE, United Kingdom
North Middlesex University Hospital
London, England, N18 1QX, United Kingdom
Royal Free Hospital
London, England, NW3 2QG, United Kingdom
St Thomas Hospital
London, England, SE1 7EH, United Kingdom
Guy's Hospital
London, England, SE1 9RT, United Kingdom
Queen Elizabeth Hospital, Woolwich
London, England, SE18 4QH, United Kingdom
King's College Hospital
London, England, SE5 9RS, United Kingdom
St George's University Hospital
London, England, SW17 0QT, United Kingdom
Royal Marsden Hospital
London, England, SW3 6JJ, United Kingdom
Royal Brompton Hospital
London, England, SW3 6NP, United Kingdom
Hammersmith Hospital
London, England, W12 0HS, United Kingdom
St Mary's Hospital
London, England, W2 1NY, United Kingdom
Charing Cross Hospital
London, England, W6 8RF, United Kingdom
Luton and Dunstable University Hospital
Luton, England, LU4 0DZ, United Kingdom
Maidstone Hospital
Maidstone, England, ME16 9QQ, United Kingdom
Manchester Royal Infirmary
Manchester, England, M13 9WL, United Kingdom
The Christie Hospital
Manchester, England, M20 4BX, United Kingdom
Wythenshawe Hospital
Manchester, England, M23 9LT, United Kingdom
North Manchester General Hospital
Manchester, England, M8 5RB, United Kingdom
Arrowe Park Hospital
Metropolitan Borough of Wirral, England, CH49 5PE, United Kingdom
The James Cook University Hospital
Middlesbrough, England, TS4 3BW, United Kingdom
Milton Keynes University Hospital
Milton Keynes, England, MK6 5LD, United Kingdom
Royal Victoria Infirmary, Newcastle
Newcastle, England, NE1 4LP, United Kingdom
Newcastle Freeman Hospital
Newcastle, England, NE7 7DN, United Kingdom
Northampton General Hospital
Northampton, England, NN1 5BD, United Kingdom
Norfolk and Norwich University Hospital
Norwich, England, NR4 7UY, United Kingdom
City Hospital Nottingham
Nottingham, England, NG5 1PB, United Kingdom
Queen's Medical Centre - Nottingham University Hospitals NHS Trust
Nottingham, England, NG7 2UH, United Kingdom
George Eliot Hospital
Nuneaton, England, CV10 7DJ, United Kingdom
Royal Oldham Hospital
Oldham, England, Ol1 2JH, United Kingdom
Princess Royal University Hospital
Orpington, England, BR6 8ND, United Kingdom
John Radcliffe Hospital
Oxford, England, OX3 9DU, United Kingdom
Derriford Hospital
Plymouth, England, PL6 8DH, United Kingdom
Poole Hospital NHS Foundation Trust
Poole, England, BH15 2JB, United Kingdom
Queen Alexandra Hospital
Portsmouth, England, PO6 3LY, United Kingdom
Whiston Hospital
Prescot, England, L35 5DR, United Kingdom
Royal Preston Hospital
Preston, England, PR2 9HT, United Kingdom
Royal Berkshire Hospital
Reading, England, RG1 5AN, United Kingdom
Alexandra Hospital, Redditch
Redditch, England, B98 7UB, United Kingdom
Queen's Hospital Romford
Romford, England, RM7 0AG, United Kingdom
Rotherham Hospital
Rotherham, England, S60 2UD, United Kingdom
Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust
Royal Tunbridge Wells, England, TN2 4QJ, United Kingdom
Salford Royal Hospital
Salford, England, M6 8HD, United Kingdom
Salisbury District Hospital
Salisbury, England, SP2 8BJ, United Kingdom
Royal Hallamshire Hospital
Sheffield, England, S10 2JF, United Kingdom
Northern General Hospital
Sheffield, England, S5 7AU, United Kingdom
Wexham Park Hospital
Slough, England, SL2 4HL, United Kingdom
South Tyneside District Hospital
South Shields, England, NE34 0PL, United Kingdom
Southampton General Hospital
Southampton, England, SO16 6YD, United Kingdom
Stepping Hill Hospital
Stockport, England, SK2 7JE, United Kingdom
University Hospital of North Tees
Stockton-on-Tees, England, TS19 8PE, United Kingdom
Royal Stoke University Hospital
Stoke-on-Trent, England, ST4 6QG, United Kingdom
Sunderland Royal Hospital
Sunderland, England, SR4 7TP, United Kingdom
King's Mill Hospital
Sutton in Ashfield, England, NG17 4JL, United Kingdom
Great Western Hospital
Swindon, England, SN3 6BB, United Kingdom
Western General Hospital
Swindon, England, SN3 6BB, United Kingdom
Musgrove Park Hospital
Taunton, England, TA1 5DA, United Kingdom
Torbay Hospital
Torquay, England, TQ2 7AA, United Kingdom
Royal Cornwall Hospital
Truro, England, TR1 3LJ, United Kingdom
Harefield Hospital
Uxbridge, England, UB9 6JH, United Kingdom
Watford General Hospital
Watford, England, WD18 0HB, United Kingdom
Southend Hospital
Westcliff-on-Sea, England, ISS0 0RY, United Kingdom
West Cumberland Hospital
Whitehaven, England, CA28 8JG, United Kingdom
Royal Albert Edward Infirmary
Wigan, England, WN1 2NN, United Kingdom
Royal Hampshire County Hospital
Winchester, England, SO22 5DG, United Kingdom
New Cross Hospital Wolverhampton
Wolverhampton, England, WV10 0QP, United Kingdom
Worcestershire Royal Hospital
Worcester, England, WR5 1DD, United Kingdom
York Teaching Hospital
York, England, Y031 8HE, United Kingdom
Antrim Area Hospital
Antrim, Northern Ireland, BT41 2RL, United Kingdom
Royal Victoria Hospital Belfast
Belfast, Northern Ireland, BT12 6BA, United Kingdom
Mater Hospital
Belfast, Northern Ireland, BT14 6AB, United Kingdom
Belfast City Hospital
Belfast, Northern Ireland, BT9 7AB, United Kingdom
Altnagelvin Hospital
Londonderry, Northern Ireland, BT47 6SB, United Kingdom
Aberdeen Royal Infirmary
Aberdeen, Scotland, AB25 2ZN, United Kingdom
Ninewells Hospital
Dundee, Scotland, DD1 9SY, United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, Scotland, EH16 4SA, United Kingdom
Glasgow Royal Infirmary
Glasgow, Scotland, G4 0SF, United Kingdom
Queen Elizabeth University Hospital, Glasgow
Glasgow, Scotland, G51 4TF, United Kingdom
Royal Alexandra Hospital
Paisley, Scotland, PA2 9PN, United Kingdom
Neville Hall Hospital
Abergavenny, Wales, NP7 7EG, United Kingdom
Glan Clwyd Hospital
Bodelwyddan, Wales, LL18 5UJ, United Kingdom
Princess of Wales Hospital
Bridgend, Wales, CF31 1RQ, United Kingdom
Cardiff and Vale University Hospital Wales
Cardiff, Wales, CF14 4XW, United Kingdom
Glangwilli Hospital
Carmarthen, Wales, SA31 2AF, United Kingdom
Grange University Hospital
Cwmbran, Wales, NP44 8YN, United Kingdom
Royal Gwent Hospital
Newport, Wales, NP20 2UB, United Kingdom
Royal Glamorgan Hospital
Pont-y-clun, Wales, CF72 8XR, United Kingdom
Morriston Hospital
Swansea, Wales, SA6 6NL, United Kingdom
Wrexham Maelor Hospital
Wrexham, Wales, LL13 7TD, United Kingdom
Ulster Hospital
Belfast, BT16 1RH, United Kingdom
Bristol Royal Childrens Hospital
Bristol, BS2 8BJ, United Kingdom
Fairfield General Hospital
Bury, BL9 7TD, United Kingdom
Leighton Hospital
Crewe, CW1 4QJ, United Kingdom
Dorset County Hospital
Dorchester, DT1 2JY, United Kingdom
Gloucester Royal Hospital
Gloucester, GL1 3NN, United Kingdom
The Princess Royal Hospital Haywards Heath
Haywards Heath, RH16 4EX, United Kingdom
St. James University Hospital
Leeds, LS9 7TF, United Kingdom
Homerton Hospital
London, E9 6SR, United Kingdom
University College London Hospital
London, NW1 2BU, United Kingdom
Chelsea and Westminster Hospital
London, SW10 9NH, United Kingdom
Queen Elizabeth and Queen Mother Hospital
Margate, CT9 4AN, United Kingdom
Newcastle Royal Victoria Infirmary (Paediatrics)
Newcastle upon Tyne, NE1 4LP, United Kingdom
North Tyneside General Hospital
North Shields, Ne29 8NH, United Kingdom
Warwick Hospital
Warwick, CV34 5BW, United Kingdom
Sandwell General Hospital
West Bromwich, B71 4HJ, United Kingdom
Related Publications (19)
Derde L, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, Beasley R, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Buxton M, Cheng AC, Cooper N, Cove M, Cremer OL, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Galea J, Goossens H, Haniffa R, Hills TE, Huang DT, Ichihara N, King A, Lamontagne F, Lawler PR, Leavis HL, Lewis RJ, Litton E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Morpeth SC, Murthy S, Netea MG, Ogungbenro K, Orr K, Parke RL, Parker JC, Patanwala AE, Pettila V, Reyes LF, Saito H, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, Tong SYC, Vaara S, Youngstein T, Zarychanski R, Green C, Higgins AM, McArthur CJ, Berry LR, Lorenzi E, Berry S, Webb SA, Angus DC, van de Veerdonk FL. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial. Thorax. 2025 Jul 15;80(8):530-539. doi: 10.1136/thorax-2024-222488.
PMID: 40360262DERIVEDREMAP-CAP Investigators; Angus DC. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial. Intensive Care Med. 2025 Apr;51(4):665-680. doi: 10.1007/s00134-025-07861-w. Epub 2025 Apr 22.
PMID: 40261382DERIVEDREMAP-CAP Investigators; Hills TE, Lorenzi E, Berry LR, Shyamsundar M, Al-Beidh F, Annane D, Arabi Y, Aryal D, Au C, Beane A, Bhimani Z, Bonten M, Bradbury CA, Brunkhorst FM, Burrell A, Buxton M, Calfee CS, Cecconi M, Cheng AC, Cove ME, Detry MA, Estcourt LJ, Fitzgerald M, Goligher EC, Goossens H, Green C, Haniffa R, Harrison DA, Hashmi M, Higgins AM, Horvat C, Huang DT, Ichihara N, Jayakumar D, Kruger PS, Lamontagne F, Lampro L, Lawler PR, Marshall JC, Mason AJ, McGlothlin A, McGuinness S, McQuilten ZK, McVerry BJ, Mouncey PR, Murthy S, Neal MD, Nichol AD, O'Kane CM, Parke RL, Parker JC, Rabindrarajan E, Reyes LF, Rowan KM, Saito H, Santos M, Saunders CT, Seymour CW, Shankar-Hari M, Sinha P, Thompson BT, Turgeon AF, Turner AM, van de Veerdonk F, Weis S, Young IS, Zarychanski R, Lewis RJ, McArthur CJ, Angus DC, Berry SM, Derde LPG, Webb SA, Gordon AC, McAuley DF. Simvastatin in Critically Ill Patients with Covid-19. N Engl J Med. 2023 Dec 21;389(25):2341-2354. doi: 10.1056/NEJMoa2309995. Epub 2023 Oct 25.
PMID: 37888913DERIVEDLOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators; Adhikari NKJ, Hashmi M, Tirupakuzhi Vijayaraghavan BK, Haniffa R, Beane A, Webb SA, Angus DC, Gordon AC, Cook DJ, Guyatt GH, Berry LR, Lorenzi E, Mouncey PR, Au C, Pinto R, Menard J, Sprague S, Masse MH, Huang DT, Heyland DK, Nichol AD, McArthur CJ, de Man A, Al-Beidh F, Annane D, Anstey M, Arabi YM, Battista MC, Berry S, Bhimani Z, Bonten MJM, Bradbury CA, Brant EB, Brunkhorst FM, Burrell A, Buxton M, Cecconi M, Cheng AC, Cohen D, Cove ME, Day AG, Derde LPG, Detry MA, Estcourt LJ, Fagbodun EO, Fitzgerald M, Goossens H, Green C, Higgins AM, Hills TE, Horvat C, Ichihara N, Jayakumar D, Kanji S, Khoso MN, Lawler PR, Lewis RJ, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, McQuilten ZK, McVerry BJ, Murthy S, Parke RL, Parker JC, Reyes LF, Rowan KM, Saito H, Salahuddin N, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tolppa T, Trapani T, Turgeon AF, Turner AM, Udy AA, van de Veerdonk FL, Zarychanski R, Lamontagne F. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. JAMA. 2023 Nov 14;330(18):1745-1759. doi: 10.1001/jama.2023.21407.
PMID: 37877585DERIVEDFischer AL, Messer S, Riera R, Martimbianco ALC, Stegemann M, Estcourt LJ, Weibel S, Monsef I, Andreas M, Pacheco RL, Skoetz N. Antiplatelet agents for the treatment of adults with COVID-19. Cochrane Database Syst Rev. 2023 Jul 25;7(7):CD015078. doi: 10.1002/14651858.CD015078.
PMID: 37489818DERIVEDWriting Committee for the REMAP-CAP Investigators; Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, Berry LR, Lorenzi E, van Kimmenade R, Gommans F, Vaduganathan M, Leaf DE, Baron RM, Kim EY, Frankfurter C, Epelman S, Kwan Y, Grieve R, O'Neill S, Sadique Z, Puskarich M, Marshall JC, Higgins AM, Mouncey PR, Rowan KM, Al-Beidh F, Annane D, Arabi YM, Au C, Beane A, van Bentum-Puijk W, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Cecconi M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Ezekowitz J, Fitzgerald M, Gattas D, Godoy LC, Goossens H, Haniffa R, Harrison DA, Hills T, Horvat CM, Ichihara N, Lamontagne F, Linstrum KM, McAuley DF, McGlothlin A, McGuinness SP, McQuilten Z, Murthy S, Nichol AD, Owen DRJ, Parke RL, Parker JC, Pollock KM, Reyes LF, Saito H, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Singh V, Turgeon AF, Turner AM, Zarychanski R, Green C, Lewis RJ, Angus DC, Berry S, Gordon AC, McArthur CJ, Webb SA. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA. 2023 Apr 11;329(14):1183-1196. doi: 10.1001/jama.2023.4480.
PMID: 37039790DERIVEDNurmi V, Knight C, Estcourt L, Hepojoki J, Lamikanra AA, Tsang HP, Roberts DJ, Polack FP, Simmonds P, Hedman K, Alvarez-Paggi D, Harvala H. The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors. J Infect Dis. 2023 Aug 11;228(3):245-250. doi: 10.1093/infdis/jiad070.
PMID: 36967714DERIVEDGoligher EC, Lawler PR, Jensen TP, Talisa V, Berry LR, Lorenzi E, McVerry BJ, Chang CH, Leifer E, Bradbury C, Berger J, Hunt BJ, Castellucci LA, Kornblith LZ, Gordon AC, McArthur C, Webb S, Hochman J, Neal MD, Zarychanski R, Berry S, Angus DC; REMAP-CAP, ATTACC, and ACTIV-4a Investigators. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA. 2023 Apr 4;329(13):1066-1077. doi: 10.1001/jama.2023.3651.
PMID: 36942550DERIVEDREMAP-CAP Writing Committee for the REMAP-CAP Investigators; Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, Al-Beidh F, Rowan KM, Berry LR, Lorenzi E, Zarychanski R, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Bhimani Z, Bihari S, Bonten MJM, Brunkhorst FM, Buzgau A, Buxton M, Carrier M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Huang DT, Horvat CM, Hunt BJ, Ichihara N, Lamontagne F, Leavis HL, Linstrum KM, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Morpeth SC, Murthy S, Neal MD, Nichol AD, Parke RL, Parker JC, Reyes LF, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Singh V, Tolppa T, Turgeon AF, Turner AM, van de Veerdonk FL, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Webb SA, Gordon AC. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910.
PMID: 35315874DERIVEDWriting Committee for the REMAP-CAP Investigators; Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM, Arnold DM, Beane A, Begin P, van Bentum-Puijk W, Berry LR, Bhimani Z, Birchall JE, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Callum JL, Chasse M, Cheng AC, Cove ME, Daly J, Derde L, Detry MA, De Jong M, Evans A, Fergusson DA, Fish M, Fitzgerald M, Foley C, Goossens H, Gordon AC, Gosbell IB, Green C, Haniffa R, Harvala H, Higgins AM, Hills TE, Hoad VC, Horvat C, Huang DT, Hudson CL, Ichihara N, Laing E, Lamikanra AA, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, MacLennan S, Marshall J, McAuley DF, McDyer JF, McGlothlin A, McGuinness S, Miflin G, Montgomery S, Mouncey PR, Murthy S, Nichol A, Parke R, Parker JC, Priddee N, Purcell DFJ, Reyes LF, Richardson P, Robitaille N, Rowan KM, Rynne J, Saito H, Santos M, Saunders CT, Serpa Neto A, Seymour CW, Silversides JA, Tinmouth AA, Triulzi DJ, Turner AM, van de Veerdonk F, Walsh TS, Wood EM, Berry S, Lewis RJ, Menon DK, McArthur C, Zarychanski R, Angus DC, Webb SA, Roberts DJ, Shankar-Hari M. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1690-1702. doi: 10.1001/jama.2021.18178.
PMID: 34606578DERIVEDKreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
PMID: 34473343DERIVEDREMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Dzavik V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froess JD, Fu Z, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Knudson MM, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Gallego Lima F, Linstrum K, Litton E, Lopez-Sendon J, Lother SA, Marten N, Saud Marinez A, Martinez M, Mateos Garcia E, Mavromichalis S, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nicolau JC, Nunez-Garcia B, Park JJ, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Pompilio M, Quigley JG, Rosenson RS, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schreiber J, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Singhal AB, Slutsky AS, Solvason D, Stanworth SJ, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Widmer RJ, Wilson JG, Yuriditsky E, Zhong Y, Berry SM, McArthur CJ, Neal MD, Hochman JS, Webb SA, Zarychanski R. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
PMID: 34351722DERIVEDATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Dzavik V, Effron MB, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, Garcia-Madrona S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Hegde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, King AJ, Knudson MM, Kornblith AE, Krishnan V, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, Lopez-Sendon J, Lopez-Sendon Moreno JL, Lother SA, Malhotra S, Marcos M, Saud Marinez A, Marshall JC, Marten N, Matthay MA, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Moore SC, Morillo Guerrero R, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nunez-Garcia B, Pandey A, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Perez Gonzalez YS, Pompilio M, Prekker ME, Quigley JG, Rost NS, Rowan K, Santos FO, Santos M, Olombrada Santos M, Satterwhite L, Saunders CT, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Shankar-Hari M, Sheehan JP, Singhal AB, Solvason D, Stanworth SJ, Tritschler T, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Wells BJ, Widmer RJ, Wilson JG, Yuriditsky E, Zampieri FG, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
PMID: 34351721DERIVEDArabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA, Beane A, Beasley R, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Buzgau A, Cheng A, De Jong M, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Fowler R, Girard TD, Goligher EC, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Huang DT, King AJ, Lamontagne F, Lawler PR, Lewis R, Linstrum K, Litton E, Lorenzi E, Malakouti S, McAuley DF, McGlothlin A, Mcguinness S, McVerry BJ, Montgomery SK, Morpeth SC, Mouncey PR, Orr K, Parke R, Parker JC, Patanwala AE, Rowan KM, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tong SYC, Turgeon AF, Turner AM, Van de Veerdonk FL, Zarychanski R, Green C, Berry S, Marshall JC, McArthur C, Angus DC, Webb SA; REMAP-CAP Investigators. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 Aug;47(8):867-886. doi: 10.1007/s00134-021-06448-5. Epub 2021 Jul 12.
PMID: 34251506DERIVEDREMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettila V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
PMID: 33631065DERIVEDUPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators. Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations. Trials. 2021 Jan 28;22(1):100. doi: 10.1186/s13063-020-04997-6.
PMID: 33509275DERIVEDTume LN, Menzies JC, Ray S, Scholefield BR; UK Paediatric Intensive Care Society Study Group. Research Priorities for U.K. Pediatric Critical Care in 2019: Healthcare Professionals' and Parents' Perspectives. Pediatr Crit Care Med. 2021 May 1;22(5):e294-e301. doi: 10.1097/PCC.0000000000002647.
PMID: 33394942DERIVEDAngus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detry M, Estcourt L, Fitzgerald M, Goossens H, Green C, Haniffa R, Higgins AM, Horvat C, Hullegie SJ, Kruger P, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, Marshall J, McAuley D, McGlothin A, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Rowan K, Sanil A, Santos M, Saunders C, Seymour C, Turner A, van de Veerdonk F, Venkatesh B, Zarychanski R, Berry S, Lewis RJ, McArthur C, Webb SA, Gordon AC; Writing Committee for the REMAP-CAP Investigators; Al-Beidh F, Angus D, Annane D, Arabi Y, van Bentum-Puijk W, Berry S, Beane A, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Rowan K, Seymour C, Turner A, van de Veerdonk F, Webb S, Zarychanski R, Campbell L, Forbes A, Gattas D, Heritier S, Higgins L, Kruger P, Peake S, Presneill J, Seppelt I, Trapani T, Young P, Bagshaw S, Daneman N, Ferguson N, Misak C, Santos M, Hullegie S, Pletz M, Rohde G, Rowan K, Alexander B, Basile K, Girard T, Horvat C, Huang D, Linstrum K, Vates J, Beasley R, Fowler R, McGloughlin S, Morpeth S, Paterson D, Venkatesh B, Uyeki T, Baillie K, Duffy E, Fowler R, Hills T, Orr K, Patanwala A, Tong S, Netea M, Bihari S, Carrier M, Fergusson D, Goligher E, Haidar G, Hunt B, Kumar A, Laffan M, Lawless P, Lother S, McCallum P, Middeldopr S, McQuilten Z, Neal M, Pasi J, Schutgens R, Stanworth S, Turgeon A, Weissman A, Adhikari N, Anstey M, Brant E, de Man A, Lamonagne F, Masse MH, Udy A, Arnold D, Begin P, Charlewood R, Chasse M, Coyne M, Cooper J, Daly J, Gosbell I, Harvala-Simmonds H, Hills T, MacLennan S, Menon D, McDyer J, Pridee N, Roberts D, Shankar-Hari M, Thomas H, Tinmouth A, Triulzi D, Walsh T, Wood E, Calfee C, O'Kane C, Shyamsundar M, Sinha P, Thompson T, Young I, Bihari S, Hodgson C, Laffey J, McAuley D, Orford N, Neto A, Detry M, Fitzgerald M, Lewis R, McGlothlin A, Sanil A, Saunders C, Berry L, Lorenzi E, Miller E, Singh V, Zammit C, van Bentum Puijk W, Bouwman W, Mangindaan Y, Parker L, Peters S, Rietveld I, Raymakers K, Ganpat R, Brillinger N, Markgraf R, Ainscough K, Brickell K, Anjum A, Lane JB, Richards-Belle A, Saull M, Wiley D, Bion J, Connor J, Gates S, Manax V, van der Poll T, Reynolds J, van Beurden M, Effelaar E, Schotsman J, Boyd C, Harland C, Shearer A, Wren J, Clermont G, Garrard W, Kalchthaler K, King A, Ricketts D, Malakoutis S, Marroquin O, Music E, Quinn K, Cate H, Pearson K, Collins J, Hanson J, Williams P, Jackson S, Asghar A, Dyas S, Sutu M, Murphy S, Williamson D, Mguni N, Potter A, Porter D, Goodwin J, Rook C, Harrison S, Williams H, Campbell H, Lomme K, Williamson J, Sheffield J, van't Hoff W, McCracken P, Young M, Board J, Mart E, Knott C, Smith J, Boschert C, Affleck J, Ramanan M, D'Souza R, Pateman K, Shakih A, Cheung W, Kol M, Wong H, Shah A, Wagh A, Simpson J, Duke G, Chan P, Cartner B, Hunter S, Laver R, Shrestha T, Regli A, Pellicano A, McCullough J, Tallott M, Kumar N, Panwar R, Brinkerhoff G, Koppen C, Cazzola F, Brain M, Mineall S, Fischer R, Biradar V, Soar N, White H, Estensen K, Morrison L, Smith J, Cooper M, Health M, Shehabi Y, Al-Bassam W, Hulley A, Whitehead C, Lowrey J, Gresha R, Walsham J, Meyer J, Harward M, Venz E, Williams P, Kurenda C, Smith K, Smith M, Garcia R, Barge D, Byrne D, Byrne K, Driscoll A, Fortune L, Janin P, Yarad E, Hammond N, Bass F, Ashelford A, Waterson S, Wedd S, McNamara R, Buhr H, Coles J, Schweikert S, Wibrow B, Rauniyar R, Myers E, Fysh E, Dawda A, Mevavala B, Litton E, Ferrier J, Nair P, Buscher H, Reynolds C, Santamaria J, Barbazza L, Homes J, Smith R, Murray L, Brailsford J, Forbes L, Maguire T, Mariappa V, Smith J, Simpson S, Maiden M, Bone A, Horton M, Salerno T, Sterba M, Geng W, Depuydt P, De Waele J, De Bus L, Fierens J, Bracke S, Reeve B, Dechert W, Chasse M, Carrier FM, Boumahni D, Benettaib F, Ghamraoui A, Bellemare D, Cloutier E, Francoeur C, Lamontagne F, D'Aragon F, Carbonneau E, Leblond J, Vazquez-Grande G, Marten N, Wilson M, Albert M, Serri K, Cavayas A, Duplaix M, Williams V, Rochwerg B, Karachi T, Oczkowski S, Centofanti J, Millen T, Duan E, Tsang J, Patterson L, English S, Watpool I, Porteous R, Miezitis S, McIntyre L, Brochard L, Burns K, Sandhu G, Khalid I, Binnie A, Powell E, McMillan A, Luk T, Aref N, Andric Z, Cviljevic S, Dimoti R, Zapalac M, Mirkovic G, Barsic B, Kutlesa M, Kotarski V, Vujaklija Brajkovic A, Babel J, Sever H, Dragija L, Kusan I, Vaara S, Pettila L, Heinonen J, Kuitunen A, Karlsson S, Vahtera A, Kiiski H, Ristimaki S, Azaiz A, Charron C, Godement M, Geri G, Vieillard-Baron A, Pourcine F, Monchi M, Luis D, Mercier R, Sagnier A, Verrier N, Caplin C, Siami S, Aparicio C, Vautier S, Jeblaoui A, Fartoukh M, Courtin L, Labbe V, Leparco C, Muller G, Nay MA, Kamel T, Benzekri D, Jacquier S, Mercier E, Chartier D, Salmon C, Dequin P, Schneider F, Morel G, L'Hotellier S, Badie J, Berdaguer FD, Malfroy S, Mezher C, Bourgoin C, Megarbane B, Voicu S, Deye N, Malissin I, Sutterlin L, Guitton C, Darreau C, Landais M, Chudeau N, Robert A, Moine P, Heming N, Maxime V, Bossard I, Nicholier TB, Colin G, Zinzoni V, Maquigneau N, Finn A, Kress G, Hoff U, Friedrich Hinrichs C, Nee J, Pletz M, Hagel S, Ankert J, Kolanos S, Bloos F, Petros S, Pasieka B, Kunz K, Appelt P, Schutze B, Kluge S, Nierhaus A, Jarczak D, Roedl K, Weismann D, Frey A, Klinikum Neukolln V, Reill L, Distler M, Maselli A, Belteczki J, Magyar I, Fazekas A, Kovacs S, Szoke V, Szigligeti G, Leszkoven J, Collins D, Breen P, Frohlich S, Whelan R, McNicholas B, Scully M, Casey S, Kernan M, Doran P, O'Dywer M, Smyth M, Hayes L, Hoiting O, Peters M, Rengers E, Evers M, Prinssen A, Bosch Ziekenhuis J, Simons K, Rozendaal W, Polderman F, de Jager P, Moviat M, Paling A, Salet A, Rademaker E, Peters AL, de Jonge E, Wigbers J, Guilder E, Butler M, Cowdrey KA, Newby L, Chen Y, Simmonds C, McConnochie R, Ritzema Carter J, Henderson S, Van Der Heyden K, Mehrtens J, Williams T, Kazemi A, Song R, Lai V, Girijadevi D, Everitt R, Russell R, Hacking D, Buehner U, Williams E, Browne T, Grimwade K, Goodson J, Keet O, Callender O, Martynoga R, Trask K, Butler A, Schischka L, Young C, Lesona E, Olatunji S, Robertson Y, Jose N, Amaro dos Santos Catorze T, de Lima Pereira TNA, Neves Pessoa LM, Castro Ferreira RM, Pereira Sousa Bastos JM, Aysel Florescu S, Stanciu D, Zaharia MF, Kosa AG, Codreanu D, Marabi Y, Al Qasim E, Moneer Hagazy M, Al Swaidan L, Arishi H, Munoz-Bermudez R, Marin-Corral J, Salazar Degracia A, Parrilla Gomez F, Mateo Lopez MI, Rodriguez Fernandez J, Carcel Fernandez S, Carmona Flores R, Leon Lopez R, de la Fuente Martos C, Allan A, Polgarova P, Farahi N, McWilliam S, Hawcutt D, Rad L, O'Malley L, Whitbread J, Kelsall O, Wild L, Thrush J, Wood H, Austin K, Donnelly A, Kelly M, O'Kane S, McClintock D, Warnock M, Johnston P, Gallagher LJ, Mc Goldrick C, Mc Master M, Strzelecka A, Jha R, Kalogirou M, Ellis C, Krishnamurthy V, Deelchand V, Silversides J, McGuigan P, Ward K, O'Neill A, Finn S, Phillips B, Mullan D, Oritz-Ruiz de Gordoa L, Thomas M, Sweet K, Grimmer L, Johnson R, Pinnell J, Robinson M, Gledhill L, Wood T, Morgan M, Cole J, Hill H, Davies M, Antcliffe D, Templeton M, Rojo R, Coghlan P, Smee J, Mackay E, Cort J, Whileman A, Spencer T, Spittle N, Kasipandian V, Patel A, Allibone S, Genetu RM, Ramali M, Ghosh A, Bamford P, London E, Cawley K, Faulkner M, Jeffrey H, Smith T, Brewer C, Gregory J, Limb J, Cowton A, O'Brien J, Nikitas N, Wells C, Lankester L, Pulletz M, Williams P, Birch J, Wiseman S, Horton S, Alegria A, Turki S, Elsefi T, Crisp N, Allen L, McCullagh I, Robinson P, Hays C, Babio-Galan M, Stevenson H, Khare D, Pinder M, Selvamoni S, Gopinath A, Pugh R, Menzies D, Mackay C, Allan E, Davies G, Puxty K, McCue C, Cathcart S, Hickey N, Ireland J, Yusuff H, Isgro G, Brightling C, Bourne M, Craner M, Watters M, Prout R, Davies L, Pegler S, Kyeremeh L, Arbane G, Wilson K, Gomm L, Francia F, Brett S, Sousa Arias S, Elin Hall R, Budd J, Small C, Birch J, Collins E, Henning J, Bonner S, Hugill K, Cirstea E, Wilkinson D, Karlikowski M, Sutherland H, Wilhelmsen E, Woods J, North J, Sundaran D, Hollos L, Coburn S, Walsh J, Turns M, Hopkins P, Smith J, Noble H, Depante MT, Clarey E, Laha S, Verlander M, Williams A, Huckle A, Hall A, Cooke J, Gardiner-Hill C, Maloney C, Qureshi H, Flint N, Nicholson S, Southin S, Nicholson A, Borgatta B, Turner-Bone I, Reddy A, Wilding L, Chamara Warnapura L, Agno Sathianathan R, Golden D, Hart C, Jones J, Bannard-Smith J, Henry J, Birchall K, Pomeroy F, Quayle R, Makowski A, Misztal B, Ahmed I, KyereDiabour T, Naiker K, Stewart R, Mwaura E, Mew L, Wren L, Willams F, Innes R, Doble P, Hutter J, Shovelton C, Plumb B, Szakmany T, Hamlyn V, Hawkins N, Lewis S, Dell A, Gopal S, Ganguly S, Smallwood A, Harris N, Metherell S, Lazaro JM, Newman T, Fletcher S, Nortje J, Fottrell-Gould D, Randell G, Zaman M, Elmahi E, Jones A, Hall K, Mills G, Ryalls K, Bowler H, Sall J, Bourne R, Borrill Z, Duncan T, Lamb T, Shaw J, Fox C, Moreno Cuesta J, Xavier K, Purohit D, Elhassan M, Bakthavatsalam D, Rowland M, Hutton P, Bashyal A, Davidson N, Hird C, Chhablani M, Phalod G, Kirkby A, Archer S, Netherton K, Reschreiter H, Camsooksai J, Patch S, Jenkins S, Pogson D, Rose S, Daly Z, Brimfield L, Claridge H, Parekh D, Bergin C, Bates M, Dasgin J, McGhee C, Sim M, Hay SK, Henderson S, Phull MK, Zaidi A, Pogreban T, Rosaroso LP, Harvey D, Lowe B, Meredith M, Ryan L, Hormis A, Walker R, Collier D, Kimpton S, Oakley S, Rooney K, Rodden N, Hughes E, Thomson N, McGlynn D, Walden A, Jacques N, Coles H, Tilney E, Vowell E, Schuster-Bruce M, Pitts S, Miln R, Purandare L, Vamplew L, Spivey M, Bean S, Burt K, Moore L, Day C, Gibson C, Gordon E, Zitter L, Keenan S, Baker E, Cherian S, Cutler S, Roynon-Reed A, Harrington K, Raithatha A, Bauchmuller K, Ahmad N, Grecu I, Trodd D, Martin J, Wrey Brown C, Arias AM, Craven T, Hope D, Singleton J, Clark S, Rae N, Welters I, Hamilton DO, Williams K, Waugh V, Shaw D, Puthucheary Z, Martin T, Santos F, Uddin R, Somerville A, Tatham KC, Jhanji S, Black E, Dela Rosa A, Howle R, Tully R, Drummond A, Dearden J, Philbin J, Munt S, Vuylsteke A, Chan C, Victor S, Matsa R, Gellamucho M, Creagh-Brown B, Tooley J, Montague L, De Beaux F, Bullman L, Kersiake I, Demetriou C, Mitchard S, Ramos L, White K, Donnison P, Johns M, Casey R, Mattocks L, Salisbury S, Dark P, Claxton A, McLachlan D, Slevin K, Lee S, Hulme J, Joseph S, Kinney F, Senya HJ, Oborska A, Kayani A, Hadebe B, Orath Prabakaran R, Nichols L, Thomas M, Worner R, Faulkner B, Gendall E, Hayes K, Hamilton-Davies C, Chan C, Mfuko C, Abbass H, Mandadapu V, Leaver S, Forton D, Patel K, Paramasivam E, Powell M, Gould R, Wilby E, Howcroft C, Banach D, Fernandez de Pinedo Artaraz Z, Cabreros L, White I, Croft M, Holland N, Pereira R, Zaki A, Johnson D, Jackson M, Garrard H, Juhaz V, Roy A, Rostron A, Woods L, Cornell S, Pillai S, Harford R, Rees T, Ivatt H, Sundara Raman A, Davey M, Lee K, Barber R, Chablani M, Brohi F, Jagannathan V, Clark M, Purvis S, Wetherill B, Dushianthan A, Cusack R, de Courcy-Golder K, Smith S, Jackson S, Attwood B, Parsons P, Page V, Zhao XB, Oza D, Rhodes J, Anderson T, Morris S, Xia Le Tai C, Thomas A, Keen A, Digby S, Cowley N, Wild L, Southern D, Reddy H, Campbell A, Watkins C, Smuts S, Touma O, Barnes N, Alexander P, Felton T, Ferguson S, Sellers K, Bradley-Potts J, Yates D, Birkinshaw I, Kell K, Marshall N, Carr-Knott L, Summers C. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
PMID: 32876697DERIVEDAngus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, Bhimani Z, Bonten M, Broglio K, Brunkhorst F, Cheng AC, Chiche JD, De Jong M, Detry M, Goossens H, Gordon A, Green C, Higgins AM, Hullegie SJ, Kruger P, Lamontagne F, Litton E, Marshall J, McGlothlin A, McGuinness S, Mouncey P, Murthy S, Nichol A, O'Neill GK, Parke R, Parker J, Rohde G, Rowan K, Turner A, Young P, Derde L, McArthur C, Webb SA. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc. 2020 Jul;17(7):879-891. doi: 10.1513/AnnalsATS.202003-192SD.
PMID: 32267771DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Steve Webb, Prof
Monash University, Study Chair REMAP-CAP Australia
- STUDY CHAIR
Colin McArthur, Dr
Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand
- STUDY CHAIR
Marc Bonten, Prof
UMC Utrecht, Study Chair REMAP-CAP Europe
- STUDY CHAIR
Lennie Derde, MD
UMC Utrecht, Coordinating Investigator REMAP-CAP Europe
- STUDY CHAIR
John Marshall, Prof
Unity Health Toronto, Study Chair REMAP-CAP Canada
- STUDY CHAIR
Derek Angus, Prof
University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
December 11, 2015
First Posted
April 13, 2016
Study Start
April 11, 2016
Primary Completion
February 1, 2026
Study Completion (Estimated)
February 1, 2028
Last Updated
July 12, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will share